glp-1 cardiovascular outcomes trial august 2025 Cardiovascular outcomes trials for GLP-1 receptor agonist glp-1 cardiovascular outcomes trial results

Plateaus are a natural part of any weight loss journey, and its good to plan ahead for them with your doctor

Novo Nordisk in March won the FDAs approval for Wegovy to lower the risk of cardiovascular death, heart attack and stroke in overweight or obese patients with cardiovascular diseases

Request a timeline for reassessing semaglutide effectiveness after 12 weeks, with clear metrics for continuing, adjusting, or pausing therapy

One of the frequently posed questions about vitamin B12 is: Feeling worse after B12 injection, is that natural? If youve embarked on B12 injections at La Vie Aesthetic Clinic expecting to enjoy enhanced energy, mood, and focus but arent feeling the anticipated benefits, youre certainly not in isolation

While subgroup numbers were small, the statistically significant reduction in surgery was observed only with semaglutide, and not with liraglutide or dulaglutide, suggesting that the choice of GLP-1RA may be clinically relevant (Table 2)